Intech Biopharm Balance Sheet Health
Financial Health criteria checks 3/6
Intech Biopharm has a total shareholder equity of NT$1.2B and total debt of NT$1.4B, which brings its debt-to-equity ratio to 122.9%. Its total assets and total liabilities are NT$2.7B and NT$1.5B respectively.
Key information
122.9%
Debt to equity ratio
NT$1.44b
Debt
Interest coverage ratio | n/a |
Cash | NT$597.73m |
Equity | NT$1.17b |
Total liabilities | NT$1.54b |
Total assets | NT$2.71b |
Financial Position Analysis
Short Term Liabilities: 6461's short term assets (NT$695.0M) exceed its short term liabilities (NT$568.7M).
Long Term Liabilities: 6461's short term assets (NT$695.0M) do not cover its long term liabilities (NT$974.5M).
Debt to Equity History and Analysis
Debt Level: 6461's net debt to equity ratio (71.7%) is considered high.
Reducing Debt: 6461's debt to equity ratio has increased from 60.7% to 122.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6461 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6461 has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 15% each year.